Insilico Drug Enters Phase III Trials
AllThingsApx · x · 2026-07-15
Nature Biotechnology reports that Insilico has initiated Phase III clinical trials for Rentosertib. This is a TNIK inhibitor aimed at idiopathic pulmonary fibrosis, highlighted as an AI-empowered drug discovery project.
The focus here isn't on a research paper but on the company's pipeline advancing to a later clinical stage, indicating that AI drug discovery is moving beyond early discovery into phases closer to validation and commercialization.
More from Companies & People
- Cordant exits stealth with an $8M seed round for payments visibility tools — LexSokolin · 2026-07-21
- Forgepoint AI launches Frank, an AI inside-sales rep for manufacturers — tkexpress11 · 2026-07-21
- Anthropic’s compute lead may be huge, but the benchmark gap is only about six months — xeophon · 2026-07-21
- Zhipu acquires a compiler-team spinout to optimize AI inference on domestic chips — zephyr_z9 · 2026-07-21
- Claude’s Delhi builders event drew 120 people to talk agentic AI and productivity — rudrank · 2026-07-21
- Why VCs Are Loudly Backing Open Source AI: Frontier Monopolies Threaten Their Survival — chris_j_paxton · 2026-07-21